XML 63 R6.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Cash flows from operating activities:    
Net loss $ (16,851,533) $ (11,883,359)
Adjustments to reconcile net loss to net cash from operating activities:    
Depreciation and amortization 721,665 356,859
Change in fair value of earn-out milestone liability (3,189,955) (3,630,861)
Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments 400,000
Stock-based compensation 2,286,388 4,604,415
Shares issues in upon vesting of stock awards 5,350
Deferred income tax asset (1,819,324)
Shares issued in exchange for services 29,841
Impairment of in-process research and development 4,510,000
Amortization of deferred finance charges and debt discount associated with note payable 386,640 199,153
Change in deferred rent liability (8,432)
Net changes in:    
Interest receivable on investments 46,940 (13,869)
Advances and deposits on clinical programs and other current assets (901,377) (362,107)
Other assets (74,341) (250,172)
Accounts payable - trade (157,689) (396,225)
Deferred revenue (500,000) (500,000)
Other accrued liabilities (611,746) 303,071
Net cash used in operating activities (20,258,982) (7,041,686)
Cash flows from investing activities:    
Purchases of investment in debt securities (23,829,982) (16,973,942)
Proceeds from sale and maturity of investment in debt securities 30,115,000 15,480,000
Purchases of property and equipment (349,158) (138,399)
Net cash provided by (used in) investing activities 5,935,860 (1,632,341)
Cash flows from financing activities:    
Proceeds from issuance of common stock equity, net of issuance costs 7,844,852 858,515
Proceeds from note payable, net of issuance costs 9,725,000
Net cash provided by financing activities 7,844,852 10,583,515
(Decrease) Increase in cash and cash equivalents (6,478,270) 1,909,488
Cash and cash equivalents at beginning of period 13,353,543 11,444,055
Cash and cash equivalents at end of period 6,875,273 13,353,543
Cash (paid for) received from:    
Interest (760,615) (512,872)
Income tax benefit 10,419,115
Cash paid for amounts included in measurement of lease liabilities:    
Operating cash flows from lease payments 485,848
Non-cash financing and investing activities    
Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments 400,000
Fair value of common stock issued as equity issuance costs and charged against paid in capital 450,000
Fair value of warrants issued in connection with the debt facility 507,116
Fair value of stock issued in exchange for cancelation of warrants 8,207
Right of use assets obtained in exchange for lease liabilities    
Operating leases 1,797,561
Realized and unrealized gains and losses, net, on investment in debt securities $ 12,906 $ 40,036